The Biggest Patent Rulings Of 2023
By Dani Kass · December 13, 2023, 4:46 PM EST
Already a subscriber? Click here to login
Analysis
By Dani Kass · December 13, 2023, 4:46 PM EST
Already a subscriber? Click here to login
Centripetal Networks, LLC v. Cisco Systems, Inc.
Virginia Eastern
Patent
February 13, 2018
Nimitz Technologies LLC v. CNET Media, Inc.
Delaware
Patent
August 30, 2021
Ironburg Inventions Ltd. v. Valve Corporation
Appellate - Federal Circuit
830 Patent Infringement (Fed. Qst.)
September 10, 2021
Nimitz Technologies LLC v. BuzzFeed, Inc.
Delaware
Patent
September 27, 2021
Amgen Inc., et al., Petitioners v. Sanofi, et al.
Supreme Court
830 Patent Infringement (Fed. Question)
November 22, 2021
Appellate - Federal Circuit
-
December 22, 2021
Nimitz Technologies LLC v. Imagine Learning, Inc.
Delaware
Patent
December 31, 2021
Mellaconic IP LLC v. TimeClock Plus, LLC.
Delaware
Patent
February 25, 2022
Nimitz Technologies LLC v. Bloomberg L.P.
Delaware
Patent
March 30, 2022
Lamplight Licensing LLC v. ABB Inc.
Delaware
Patent
March 30, 2022
Mellaconic IP LLC v. Deputy, Inc.
Delaware
Patent
April 27, 2022
VLSI Technology LLC v. Intel Corporation
Appellate - Federal Circuit
830 Patent Infringement (Fed. Qst.)
June 15, 2022
Lamplight Licensing LLC v. Ingram Micro, Inc.
Delaware
Patent
July 31, 2022
District Of Columbia
Civil Rights: Other
May 10, 2023
November 06, 2024
How The Patent System May Look After Trump's ReturnOctober 17, 2024
Justices Urged To Fix 'Novel Misreading' Of IP Safe HarborOctober 07, 2024
Fed. Circ. Questions If Safer OxyContin Profits Came From IPSeptember 27, 2024
Kappos' Bayh-Dole Warning To Clients Draws DebateSeptember 24, 2024
Novo Nordisk Tells Sens. Ozempic Costs Are Linked To PBMsAugust 13, 2024
Entresto Release Delayed As Novartis Goes To Fed. Circ.August 06, 2024
Fed. Circ. Told Edwards Filed Safe Harbor Suit With Bad IntentJuly 10, 2024
Drug Pricing, Overreach Dominate IP Disclaimer FeedbackMay 28, 2024
Edwards Urges Full Fed. Circ. To Limit FDA Safe HarborApril 05, 2024
Judge Lourie's Dissent Revives Debate Over FDA Safe Harbor